Cancer therapies cause HTN through a variety of mechanisms including direct effects on vascular endothelial cells or indirect renal effects and are most notably seen with vascular endothelial growth factor (VEGF) inhibitors such as, tyrosine kinase inhibitors, proteasome inhibitors, calcineurin inhibitors and adjunctive therapies like corticosteroids, exogenous erythropoietin, and non-steroidal anti-inflammatory drugs39. Here, VEGFA is linked to hypertensive disorder.